Cizzle Bio Welcomes Dr. Kevin King to Clinical Advisory Team
Cizzle Bio, Inc. is pleased to announce that Kevin King, M.D., a board-certified radiation oncologist at City of Hope in Chicago, has joined our Clinical Advisory Team.
Dr. King brings a wealth of expertise in advanced radiation therapy techniques, including stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), and intensity-modulated radiation therapy (IMRT). He is recognized as a leader in the use of SBRT for treating early-stage lung cancer—delivering highly precise, non-invasive therapy in just a few sessions for patients who may not be surgical candidates. His work in this area has helped expand access to curative treatment options and improve patient quality of life.
His broader clinical focus includes treating oligometastatic disease with an accelerated, patient-centered approach—aligning closely with our mission to improve outcomes through earlier, more effective intervention.
After earning his medical degree from Rush Medical College, Dr. King completed his radiation oncology residency at Rush University Medical Center, where he served as chief resident and was named Resident of the Year. He is an active member of leading professional organizations such as the American Society for Radiation Oncology and the American Society of Clinical Oncology.
Dr. King’s dedication to advancing cancer care and his deep clinical insight will be invaluable as we continue to expand the reach and impact of our minimally invasive, biomarker-based blood tests for the early detection of lung and gastric cancers. His guidance will help ensure that our innovations integrate seamlessly into clinical practice, supporting physicians and empowering patients nationwide.
Please join us in welcoming Dr. King to the Cizzle Bio team.
Detect Early. Save Lives.
